Mucormycosis: Its contemporary face and management strategies
Journal
The Lancet Infectious Diseases
Journal Volume
11
Journal Issue
4
Pages
301-311
Date Issued
2011
Author(s)
Singh N.
Abstract
Several countries have seen rising frequencies of mucormycosis among patients with haematological disorders, malignancies, or diabetes mellitus, and among transplant recipients. Growing numbers of immunocompromised hosts, widespread use of antifungal agents inactive against mucormycosis, or other unidentified factors, could be contributing to this situation. The predominant clinical manifestations of mucormycosis vary from host to host. Additionally, risk factors specific to different subgroups have been identified, such as leukaemia, allogeneic haemopoietic stem-cell transplant, voriconazole prophylaxis, diabetes, and malnutrition. We summarise the current state of knowledge of characteristics and risk factors and discuss topical developments in therapeutic methods and strategies in the management of mucormycosis. © 2011 Elsevier Ltd.
Other Subjects
amphotericin B; amphotericin B lipid complex; calcineurin inhibitor; colistin; deferasirox; echinocandin; gamma interferon; granulocyte macrophage colony stimulating factor; hydroxymethylglutaryl coenzyme A reductase inhibitor; mammalian target of rapamycin; posaconazole; triazole derivative; voriconazole; allogeneic hematopoietic stem cell transplantation; clinical feature; diabetes mellitus; granulocyte transfusion; human; hyperbaric oxygen; infection prevention; leukemia; malnutrition; mucormycosis; priority journal; review; risk factor; Humans; Immunocompromised Host; Incidence; Mucormycosis; Risk Factors
Type
review